Advertisement
News
Subscribe to MDT Magazine News

Vaccine boosts your immune system

December 14, 2010 9:38 am | by EurekAlert | Comments

(University of Copenhagen) Researchers at BRIC, the University of Copenhagen, have discovered for the first time a protein normally found in the body that can act to prevent chronic tissue inflammation. When administered in the form of a therapeutic vaccine it is able to...

TOPICS:

Allergy treatment may cause new allergy

December 14, 2010 9:38 am | by EurekAlert | Comments

(Lund University) Allergic contact dermatitis from aluminium has previously been considered very unusual. However, there are now reports of pruritic nodules and aluminium allergy arising after vaccinations or treatments for allergies. Researcher Eva Netterlid has studied the...

TOPICS:

Tolerx launches Phase 1 trial of cancer treatment

December 14, 2010 9:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Cambridge biotech Tolerx Inc. said today that it has initiated a Phase 1 clinical trial of its TRX518, a therapy designed to enhance the immune system by enabling T cells to be more effective in attacking cancer cells.

Advertisement

Biotech startup Tesaro lands licensing deal for cancer treatment

December 14, 2010 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Tesaro Inc. has signed a deal with Miami-based OPKO Health Inc. that will bring the Boston firm exclusive rights to develop, manufacture, commercialize and distribute rolapitant, a cancer-related treatment, in return for up to $121 million in payments to OPKO.

Reportlinker Adds European Markets for Video, High-Tech and Integrated OT Equipment 2011

December 14, 2010 9:35 am | by Bio-Medicine.Org | Comments

NEW YORK, Dec. 14, 2010  /- Reportlinker.com announces that a new market research report is available in its catalogue: European Markets for Video, High-Tech and Integrated OT Equipment 2011...

TOPICS:

Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Staging and Prostate Cancer Recurrence Study

December 14, 2010 9:35 am | by Bio-Medicine.Org | Comments

NEW YORK, Dec. 14, 2010 /- A new study in the journal Cancer shows that staging prostate cancer that has not metastasized beyond the prostate gland does predict the outcome, prognosis or risk of cancer recurrence after a radical prostatectomy. "This study confirms what many prostate...

TOPICS:

UBM Canon Launches Medical Manufacturing Events in India and Brazil

December 14, 2010 9:35 am | by Bio-Medicine.Org | Comments

LOS ANGELES, Dec. 14, 2010 /- UBM Canon today announced medical manufacturing event plans for two fast-growth BRIC markets, India and Brazil, utilizing respectively its long established MEDTEC and Medical Design & Manufacturing (MD&M) brands. In October 19-20, 2011, the MEDTEC...

TOPICS:

Reportlinker Adds Corporate Strategies in Consumer Health 2010

December 14, 2010 9:35 am | by Bio-Medicine.Org | Comments

NEW YORK, Dec, 14, 2010 /- Reportlinker.com announces that a new market research report is available in its catalogue: Corporate Strategies in Consumer Health 2010 http://www.reportlinker.com/p0338740/Corporate-Strategies-in-Consumer-Health-2010.html The consumer health market enjoyed...

TOPICS:
Advertisement

Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011

December 14, 2010 9:34 am | by Bio-Medicine.Org | Comments

NEW YORK, Dec. 14, 2010 /- Reportlinker.com announces that a new market research report is available in its catalogue: European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011...

TOPICS:

Reportlinker Adds U.S. Market for Patient Monitoring Devices 2011

December 14, 2010 9:34 am | by Bio-Medicine.Org | Comments

NEW YORK, Dec. 14, 2010 /- Reportlinker.com announces that a new market research report is available in its catalogue: U.S. Market for Patient Monitoring Devices 2011 http://www.reportlinker.com/p0339836/US-Market-for-Patient-Monitoring-Devices-2011.html In 2010, the U.S. patient...

TOPICS:

Rolaids Extra Strength Softchews, Rolaids Extra Strength plus Gas Softchews, Rolaids Multi-Symptom plus Anti-Gas Softchews: Recall - Foreign Materials in Products

December 14, 2010 9:31 am | by U.S. Food & Drug Administration | Comments

Reports of foreign materials in the product, including metal and wood particles.

TOPICS:

Emergency Medical reviewing strategic options

December 14, 2010 7:45 am | by The Associated Press | Comments

GREENWOOD VILLAGE, Colo. (AP) — Ambulance services provider Emergency Medical Services Corp. said Tuesday that it is reviewing strategic alternatives for the company, but did not provide details on its potential options.The company said it will not disclose developments from the review unless the...

C.R. Bard expects 14 pct earnings growth in 2011

December 14, 2010 7:45 am | by The Associated Press | Comments

Medical device maker C.R. Bard Inc. said Tuesday that it expects 2011 earnings per share to grow 14 percent compared with its forecast for this year, excluding the impact of items that can affect comparisons between the two years.The Murray Hill, N.J., company also expects sales growth to range...

Charles River Labs plans to shed China facilities

December 14, 2010 7:32 am | by Mass High Tech: The Journal of New England Technology | Comments

Charles River Laboratories International Inc., the Wilmington-based pharmaceutical and biotech services company, said it plans to seek "strategic alternatives" for a U.S. Phase 1 research clinic and a pre-clinical research facility in China.

Pulmatrix lands $5.7M DARPA award

December 14, 2010 6:40 am | by Mass High Tech: The Journal of New England Technology | Comments

Lexington biotech firm Pulmatrix Inc. has won a $5.7 million grant from the Defense Advanced Research Projects Agency, part of the U.S. Department of Defense, to develop technology aimed at treating and preventing respiratory infections due to weaponized, engineered or naturally occurring pathogens.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading